MetaVia Inc. is trading 10.6% up at $2.71 following news that three late-breaking posters were accepted for presentation at the American Diabetes Association (ADA) 2026 Scientific Sessions.
- The accepted abstracts feature DA-1726 and vanoglipel, highlighting the company's obesity and cardiometabolic pipeline.
- Market commentators suggest the conference news is driving significant momentum in the thinly traded micro-cap biotech stock.